Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
0.3250
-0.0257 (-7.33%)
At close: Jun 26, 2025, 4:00 PM
0.3390
+0.0140 (4.31%)
Pre-market: Jun 27, 2025, 5:33 AM EDT
Mersana Therapeutics Stock Forecast
MRSN's stock price has decreased by -84.52% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts that cover Mersana Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $5.75, which forecasts a 1669.23% increase in the stock price over the next year. The lowest target is $3 and the highest is $10.
Price Target: $5.75 (+1669.23%)
Analyst Consensus: Strong Buy
* Price targets were last updated on May 16, 2025.
Analyst Ratings
The average analyst rating for Mersana Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 2 | 2 | 2 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 7 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $9 → $10 | Strong Buy | Maintains | $9 → $10 | +2,976.92% | May 16, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +1,438.46% | May 16, 2025 |
| William Blair | William Blair | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Feb 6, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $6 → $5 | Strong Buy | Maintains | $6 → $5 | +1,438.46% | Aug 27, 2024 |
| Baird | Baird | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +823.08% | Aug 14, 2024 |
Financial Forecast
Revenue This Year
23.18M
from 40.50M
Decreased by -42.77%
Revenue Next Year
23.48M
from 23.18M
Increased by 1.30%
EPS This Year
-0.64
from -0.56
EPS Next Year
-0.58
from -0.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 36.5M | 44.9M | 43.6M | ||
| Avg | 23.2M | 23.5M | 18.1M | ||
| Low | 2.7M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -9.8% | 93.9% | 85.6% | ||
| Avg | -42.8% | 1.3% | -23.1% | ||
| Low | -93.3% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.34 | -0.14 | -0.48 | ||
| Avg | -0.64 | -0.58 | -0.75 | ||
| Low | -0.75 | -0.87 | -0.87 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.